About this Research Topic
In the last few years, conventional immunosuppressive therapies – characterized by an often unspecific mechanism of action and complicated by frequent and serious side effects – are gradually but consistently being replaced with biologic agents in autoimmune rheumatic (RA, SLE, SSc, SS, PM, DM, APS) and inflammatory rheumatic diseases (SpA). In contrast to traditional immunosuppressive strategies, biologic drugs show selectivity of action towards specific targets and are currently employed to induce remission or treat specific organ involvements in autoimmune rheumatic and related diseases and inflammatory rheumatic diseases. Nevertheless, in some cases, biologic drugs have failed to meet their primary end-points in randomized-controlled trials, especially in complicated diseases such as SLE and SSc. This has led to further changes to therapies currently used, development of new approaches, as well as the urgent need to identify biomarkers of response to therapy. The latter should be particularly relevant in identifying patients potentially susceptible to the effects of the therapy.
The scope of this Research Topic is to provide a forum for an updated overview on the progress and advances in the research of new biomarkers of response to biologic drugs in autoimmune rheumatic and inflammatory rheumatic diseases and their potential role as indicators of personalized treatment options. We welcome manuscripts reporting Original Research clinical data, validity processes, methodological aspects on predictive biomarkers of treatment response. Reviews, Mini-Reviews, Perspectives and Opinions are also welcome to complete insight into current and new available predictive biomarkers.
Keywords: Autoimmune rheumatic diseases, inflammatory rheumatic diseases, biologics, biomarkers, response to therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.